Business Wire

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

Share

The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.

Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization. Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts. The parties would share both funding for the discovery and development of the programs and financials resulting from the commercialization of any eventual drug candidates.

“This agreement with EQRx further validates Aurigene’s proven expertise in discovery and preclinical development of novel therapeutics and moves Aurigene forward into building a global oncology franchise participating in the end-to-end value chain,” said Murali Ramachandra, Ph.D., Chief Executive Officer of Aurigene. “We are excited to collaborate with EQRx and contribute to developing and delivering innovative medicines to patients at more affordable prices.”

“We are pleased to partner with Aurigene to expand our future pipeline and accelerate the discovery of next-generation therapeutics,” said Carlos Garcia-Echeverria, PhD, chief of Rx creation at EQRx. “Our combined efforts will focus on some of the most high-impact therapeutic targets across oncology and immune-inflammatory diseases. Given our mission, we believe these future programs hold the potential to create important treatments for patients and drive meaningful savings for healthcare systems around the world.”

About Aurigene
Aurigene Discovery Technologies Limited is a clinical stage biotech company committed to bringing novel therapeutics for the treatment of cancer and inflammation and a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY). Based in Bengaluru and Kuala Lumpur, Aurigene has developed deep expertise in cancer and inflammatory disorders, and has continuously invested in its people resources and infrastructure over the years. In the two decades of working with Pharma, Biotech and Academic partners, Aurigene has contributed to delivering 16 small molecule and peptide drug candidates, currently in clinical development. Aurigene has also out-licensed several first-in-class and best-in-class compounds to pharma and biotech companies for global clinical development, while undertaking clinical POC studies for a few programs on its own. For more information, please visit Aurigene’s website at www.aurigene.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aurigene Contact:
Subir Dubey
Vice President and Head of Business Development
subir_d@aurigene.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Watts Water Technologies Completes WAVE Water Stewardship Verification17.8.2022 17:00:00 CEST | Press release

Watts Water Technologies, Inc. — one of the world’s leading manufacturers and providers of plumbing, heating, and water quality products and solutions — has successfully completed verification for The Water Council’s WAVE: Water Stewardship Verified program, indicating the company has assessed water-related risk across the enterprise, identified the highest water-related impacts using credible water-related data and implemented best practice in improving water stewardship performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005123/en/ (Graphic: Business Wire) During the WAVE process, Watts prioritized eight of its sites with the highest water risk, identified the watersheds in which it operates, conducted a water balance to learn more about its water inputs and outputs, and engaged the community around its selected sites. As a result, Watts took a variety of actions at the local and global level to reduce water

Blockchain protocol for metaverses, Meta0, to launch at Gamescom17.8.2022 15:16:00 CEST | Press release

Meta0, a new blockchain startup that connects metaverses and blockchain ecosystems through a Layer 0 protocol, will officially launch at Gamescom in Cologne, Germany. Meta0's website is now live at www.meta0.org. Meta0 provides the tools game developers need to easily reach players on every blockchain while also spending less time, money, and personnel on the development process itself. As a one-stop shop for game developers, they remove the technical complexities of blockchain integration by providing intuitive API and SDK-based solutions that offer cross-chain support. "With our technology, there won't be any 'blockchain wars' like there were with consoles," said Inal Kardanov, Chief Technology Officer of Meta0. "This means players get the best game possible, while developers and publishers reach as many gamers as possible regardless of preferred blockchain." In its current state, blockchain games are highly dependent on the individual chains they are built on. Meta0 will change that

CORRECTING and REPLACING: Pharmasimple Announces Its Decision to Acquire an Equity Stake in Phytocann Group17.8.2022 15:14:00 CEST | Press release

Headline of release dated August 16, 2022, should read: Pharmasimple Announces Its Decision to Acquire an Equity Stake in Phytocann Group (instead of Phytocann Group announces its acquisition of a stake in Pharmasimple). Also, first sentence of second paragraph should read: Pharmasimple is delighted to acquire a 5% equity stake in Phytocann Group for the sum of 5 million euros (instead of Phytocann Group is delighted to acquire a 5% stake in Pharmasimple for the sum of 5 million euros). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005631/en/ The updated release reads: PHARMASIMPLE ANNOUNCES ITS DECISION TO ACQUIRE AN EQUITY STAKE IN PHYTOCANN GROUP Phytocann Group, a vertically integrated company and European CBD pioneer, is proud to announce a partnership with Pharmasimple, a company listed on Euronext Growth Paris and industry leader in Belgium. This strategic rapprochement opens up a new era for the distribution o

Bacardi Limited Welcomes Consumer Goods Executive Dave Ingram to Lead Operations17.8.2022 15:00:00 CEST | Press release

Bacardi Limited, the world’s largest privately held spirits company, today announces the appointment of Dave Ingram as Chief Supply Chain Officer. Dave brings 30 years of supply chain and strategic sourcing experience to Bacardi where he will lead the end-to-end supply chain experience -- from achieving our goal of sustainably sourcing key ingredients, to leading operations sites across the globe, to managing a robust supply chain track that brings products to shelves and consumers’ hands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005218/en/ Bacardi Limited announces the appointment of Dave Ingram as Chief Supply Chain Officer (Photo: Business Wire) Dave will report to Chief Executive Officer Mahesh Madhavan and joins the company’s Global Leadership Team effective September 1, 2022. He will be based in Geneva, Switzerland. This appointment follows the retirement of Jean-Marc Lambert after more than 20 years with t

Prosimo Delivers Industry First Full-Stack NetDevOps Toolkit for Multi-Cloud Networking17.8.2022 15:00:00 CEST | Press release

Prosimo, the Application Experience Infrastructure company, introduced a new NetDevOps Infrastructure-as-Code (IaC) Toolkit that enables enterprises to accelerate the deployment of cloud networking. Deployed by F500 companies and large enterprises, the Prosimo Full-Stack Cloud Transit with the new IaC Toolkit provides complete orchestration of cloud networking services required to connect, scale, and secure enterprise applications with complete visibility across a multi-cloud infrastructure, which reduces the network delivery lifecycle and adds implicit zero-trust while delivering compelling autonomous networking capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005147/en/ Multicloud transit with Terraform: https://learn.prosimo.io/youtube-all-videos/multicloud-transit-with-terraform-2 (Graphic: Prosimo) Learn more: Prosimo IaC toolkit video "According to ESG's Distributed Cloud research, organizations are a